The tumour-associated gene BCL9L, as a coactivator of β-catenin is involved in Wnt/β-catenin signalling, was identified to be exclusively mutated at the 5′ and 3’ UTR of BC patients. This evidence concerns the gene BCL9L and breast cancer.